VolitionRx Limited Completes $12.8 Million Underwritten Public Offering

Represented VolitionRx Limited (NYSE MKT: VNRX) in its underwritten public offering of 3,769,231 shares of Common Stock, including 565,384 shares sold pursuant to the exercise in full of the underwriters’ overallotment option, at a public offering price of $3.25 per share for net proceeds of approximately $12.8 million. VolitionRx intends to use the net proceeds from the offering for continued product development, clinical studies, production commercialization, working capital and other general corporate purposes.

VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. VolitionRx’s research and development activities are currently centered in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the United States, and, ultimately, worldwide.